Moreover, glial fibrillary acidic protein (GFAP), a marker of glial activation, has been linked to disease severity and poorer progression in Alzheimer’s disease (AD), frontotemporal dementia (FTD), and the alpha-synucleinopathy dementia with Lewy bodies (DLB) [9–11]. The gene discussed is GFAP; the disease is synucleinopathy.